🔎 Trials Near Me

Nyumbani › Limfoma › Massachusetts › Boston

Majaribio ya kliniki ya Limfoma katika Boston, MA

Masomo 33 ya Limfoma yanatafuta washiriki katika vituo vya Boston na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.

Maandishi rasmi ya utafiti (Kiingereza)

Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

InaajiriHatua 1
  • Beth Israel Deaconess Medical Center - Research, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 30 Sep 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

InaajiriHatua 2
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 30 Sep 2026 · NCT07015242

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

Inaajiri
  • Mass General Hospital, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Sep 2026 · NCT07013435

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

Inaajiri
  • Mass General Brigham, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Sep 2026 · NCT07014293

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

InaajiriHatua 1/2
  • Dana Farber Cancer Institute., Boston
Hadi umri 25 · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT04094610

Epco, Zanu, Ritux for R/R FL or MZL

InaajiriHatua 2
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06563596

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

InaajiriHatua 1/2
  • Research Site, Boston
  • Research Site, Boston
Umri 12 na zaidi · Jinsia zote · Imesasishwa 14 Sep 2026 · NCT06137144

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

InaajiriHatua 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 21 Years · Jinsia zote · Imesasishwa 11 Sep 2026 · NCT04870944

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

InaajiriHatua 1/2
  • Massachusetts General Hospital, Boston
Umri 12 na zaidi · Jinsia zote · Imesasishwa 3 Sep 2026 · NCT04588922

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

InaajiriHatua 1/2
  • Massachusetts General Hospital, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT04104776

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

InaajiriHatua 4
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Ago 2026 · NCT07426484

The CARDIOPROTECT Trial

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 27 Jul 2026 · NCT07654426

DALY II USA/ MB-CART2019.1 for DLBCL

InaajiriHatua 2
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Jul 2026 · NCT04792489

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

InaajiriHatua 1/2
  • Call for Information (Investigational Site 0026), Boston
6 Months – 17 Years · Jinsia zote · Imesasishwa 6 Jul 2026 · NCT02332668

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

InaajiriHatua 1/2
  • Dren Investigational Site, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Jun 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

InaajiriUtafiti wa uchunguzi
  • Dana-Farber Cancer Institute, Boston
Umri wote · Jinsia zote · Imesasishwa 18 Mei 2026 · NCT01790152

Remote Monitoring and Symptom Management Digital Application

Inaajiri
  • Massachusetts General Hospital, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Apr 2026 · NCT07553572

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Inaajiri
  • Massachusetts General Hospital Cancer Center, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 21 Apr 2026 · NCT05646576

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

InaajiriHatua 1/2
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 16 Apr 2026 · NCT03328078

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Inaajiri
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Apr 2026 · NCT06923397

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Mac 2026 · NCT06510309

Odronextamab in Low Tumor Volume Advanced FL

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Mac 2026 · NCT07128641

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Mac 2026 · NCT06510361

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 5 Mac 2026 · NCT05800366

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

InaajiriHatua 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Feb 2026 · NCT06854003

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

InaajiriHatua 1
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Feb 2026 · NCT06475235

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Inaajiri
  • Brigham & Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 9 Feb 2026 · NCT04368702

Avo In R/R And Previously Untreated MCL

InaajiriHatua 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 21 Jan 2026 · NCT04855695

Mosunetuzumab for CLL MRD Clearance

InaajiriHatua 1/2
  • Brigham & Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 15 Des 2025 · NCT07052695

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

InaajiriHatua 2
  • Dana Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 5 Des 2025 · NCT06986174

HEME Home Transfusion Program

Inaajiri
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Sep 2025 · NCT06487247

Majaribio ya Limfoma katika miji mingine

Masomo mengine katika Boston

Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.